focus -WSS

focus

author：leisure time 2025-09-28 11:19:34 Page View：9

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 'Little Tech' descents on D.C., wanting a say in how AI is regulated
Next article： Walensky prepares to leave CDC — and Congress — behind

explore

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Why Titanic fascinates society, still drawing tours to the wreckage

8:30ApartoftheTitanic'sbow,viewedintheAtlanticOcean,northofNewfoundlandin1996.XavierDesmier/Gamma-Ra

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

UnitedHealth CEO's Medicaid comments send insurer stocks diving

UnitedHealthGroupCEOAndrewWittysaidthecompanywasbeginningtoseea“disturbance”initsMedicaidmedicalcost

focus

knowledge

explore

UnitedHealth CEO's Medicaid comments send insurer stocks diving